Know Cancer

or
forgot password

Epigenetic Testing for Breast Cancer Risk Stratification


N/A
30 Years
79 Years
Not Enrolling
Female
Breast Cancer

Thank you

Trial Information

Epigenetic Testing for Breast Cancer Risk Stratification


Inclusion Criteria:



- Women between the ages of 30 and 79.

- Untreated stage 1 - 3 invasive breast cancer or a woman never diagnosed with breast
cancer.

- BI-RADS 1, 2, or 3 breast imaging within 12 months for women >40 years of age
recruited into the control group.

Exclusion Criteria:

- <30 or >80 years of age

- Unable to provide informed consent

- Presence of an undefined palpable or mammographic breast lesion suspicious for
malignancy (BIRADS 4 or 5)

- Breast implants

- Bilateral prophylactic mastectomy

- Any prior breasts irradiation

- Any systemic chemotherapy in the past

- Performance status that restricted normal activity for a significant portion of the
day

- Use of luteinizing-hormone-releasing-hormone (LHRH) analogs, prolactin inhibitors,
antiandrogens, or systemic glucocorticoids within three months

- Ever use of tamoxifen, raloxifene, or other SERMs

- Ever use of aromatase inhibitors

- Pregnancy or lactation within six months

- Bleeding diathesis of any kind

1. Inherited coagulation disorder

2. Current coumadin use

3. Use of drugs that inhibit platelet aggregation within 10 days

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Principal Investigator

David Euhus, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

UT Southwetsren Medical Center

Authority:

United States: Army Medical Research and Materiel Command (USAMRMC)

Study ID:

STU 092011-047

NCT ID:

NCT01501656

Start Date:

January 2012

Completion Date:

January 2015

Related Keywords:

  • Breast Cancer
  • Breast Neoplasms

Name

Location

Ut Southwestern Medical CenterDallas, Texas  75390